Tapestry Pharmaceuticals, Inc.
Records under this name other than the patents Tapestry Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 16 patents it holds.
Back to Tapestry Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,745,650 | 9,10-α,α-OH-taxane analogs and methods for production thereof Term ended Term ended Sep 28, 2025 · From the USPTO record | Term ended | Term ended Sep 28, 2025 | From the USPTO record |
| US 7,879,904 | 9, 10-α,α-OH-taxane analogs and methods for production thereof Term ended Term ended Sep 27, 2024 · From the USPTO record | Term ended | Term ended Sep 27, 2024 | From the USPTO record |
| US 9,402,824 | 9,10-α, α-OH-taxane analogs and methods for production thereof Term ended Ended no later than Sep 27, 2024 · From the USPTO record | Term ended | Ended no later than Sep 27, 2024 | From the USPTO record |
| US 9,820,962 | 9, 10-α, α-oh-taxane analogs and methods for production thereof Term ended Ended no later than Sep 27, 2024 · From the USPTO record | Term ended | Ended no later than Sep 27, 2024 | From the USPTO record |
| US 10,238,621 | 9,10-Alpha,Alpha-OH-Taxane Analogs and Methods for Production Thereof Term ended Term ended Sep 27, 2024 · Low confidence | Term ended | Term ended Sep 27, 2024 | Low confidence |
| US 10,639,293 | 9,10-α,α-OH-taxane analogs and methods for production thereof Term ended Term ended Sep 27, 2024 · From the USPTO record | Term ended | Term ended Sep 27, 2024 | From the USPTO record |
| US 6,977,295 | Locked nucleic acid hybrids and methods of use Formerly held Term ended Term ended Apr 21, 2020 · From the USPTO record | Term ended | Term ended Apr 21, 2020 | From the USPTO record |
| US 6,245,565 | Recombinase Mediated DNA modifications Formerly held Term ended Term ended Apr 28, 2019 · From the USPTO record | Term ended | Term ended Apr 28, 2019 | From the USPTO record |
| US 6,107,497 | Intermediate for use in docetaxel synthesis and production method therefor Term ended Term ended Mar 19, 2016 · From the USPTO record | Term ended | Term ended Mar 19, 2016 | From the USPTO record |
| US 6,825,166 | Molecular conjugates for use in treatment of cancer Lapsed on the fee record Ended Nov 30, 2012 · From the USPTO record | Lapsed on the fee record | Ended Nov 30, 2012 | From the USPTO record |